TY - JOUR
T1 - Nitro-fatty acids are formed in response to virus infection and are potent inhibitors of STING palmitoylation and signaling
AU - Hansen, Anne Louise
AU - Buchan, Gregory J.
AU - Rühl, Michael
AU - Mukai, Kojiro
AU - Salvatore, Sonia R.
AU - Ogawa, Emari
AU - Andersen, Sidsel D.
AU - Iversen, Marie B.
AU - Thielke, Anne L.
AU - Gunderstofte, Camilla
AU - Motwani, Mona
AU - Møller, Charlotte T.
AU - Jakobsen, Andreas S.
AU - Fitzgerald, Katherine A.
AU - Roos, Jessica
AU - Lin, Rongtuan
AU - Maier, Thorsten J.
AU - Goldbach-Mansky, Raphaela
AU - Miner, Cathrine A.
AU - Qian, Wei
AU - Miner, Jonathan J.
AU - Rigby, Rachel E.
AU - Rehwinkel, Jan
AU - Jakobsen, Martin R.
AU - Arai, Hiroyuki
AU - Taguchi, Tomohiko
AU - Schopfer, Francisco J.
AU - Olagnier, David
AU - Holm, Christian K.
N1 - Publisher Copyright:
© 2018 National Academy of Sciences. All rights reserved.
PY - 2018/8/14
Y1 - 2018/8/14
N2 - The adaptor molecule stimulator of IFN genes (STING) is central to production of type I IFNs in response to infection with DNA viruses and to presence of host DNA in the cytosol. Excessive release of type I IFNs through STING-dependent mechanisms has emerged as a central driver of several interferonopathies, including systemic lupus erythematosus (SLE), Aicardi–Goutières syndrome (AGS), and stimulator of IFN genes-associated vasculopathy with onset in infancy (SAVI). The involvement of STING in these diseases points to an unmet need for the development of agents that inhibit STING signaling. Here, we report that endogenously formed nitro-fatty acids can covalently modify STING by nitro-alkylation. These nitro-alkylations inhibit STING palmitoylation, STING signaling, and subsequently, the release of type I IFN in both human and murine cells. Furthermore, treatment with nitro-fatty acids was sufficient to inhibit production of type I IFN in fibroblasts derived from SAVI patients with a gain-of-function mutation in STING. In conclusion, we have identified nitro-fatty acids as endogenously formed inhibitors of STING signaling and propose for these lipids to be considered in the treatment of STING-dependent inflammatory diseases.
AB - The adaptor molecule stimulator of IFN genes (STING) is central to production of type I IFNs in response to infection with DNA viruses and to presence of host DNA in the cytosol. Excessive release of type I IFNs through STING-dependent mechanisms has emerged as a central driver of several interferonopathies, including systemic lupus erythematosus (SLE), Aicardi–Goutières syndrome (AGS), and stimulator of IFN genes-associated vasculopathy with onset in infancy (SAVI). The involvement of STING in these diseases points to an unmet need for the development of agents that inhibit STING signaling. Here, we report that endogenously formed nitro-fatty acids can covalently modify STING by nitro-alkylation. These nitro-alkylations inhibit STING palmitoylation, STING signaling, and subsequently, the release of type I IFN in both human and murine cells. Furthermore, treatment with nitro-fatty acids was sufficient to inhibit production of type I IFN in fibroblasts derived from SAVI patients with a gain-of-function mutation in STING. In conclusion, we have identified nitro-fatty acids as endogenously formed inhibitors of STING signaling and propose for these lipids to be considered in the treatment of STING-dependent inflammatory diseases.
KW - IFN
KW - Nitro-fatty acids
KW - Palmitoylation
KW - SAVI
KW - STING
UR - http://www.scopus.com/inward/record.url?scp=85052738022&partnerID=8YFLogxK
U2 - 10.1073/pnas.1806239115
DO - 10.1073/pnas.1806239115
M3 - Article
C2 - 30061387
AN - SCOPUS:85052738022
SN - 0027-8424
VL - 115
SP - E7768-E7775
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 33
ER -